GTx, Inc. (Nasdaq: GTXI) today reported financial results for the third quarter ended September 30, 2014 and highlighted recent accomplishments and upcoming milestones. In addition, management outlined its refocused development strategy to target the androgen receptor in women with advanced breast cancer using enobosarm, the Company’s oral nonsteroidal selective androgen receptor modulator. The Company also highlighted clinical progress with GTx-758, its oral nonsteroidal selective estrogen receptor alpha agonist, being studied for secondary hormonal therapy in men with castration resistant prostate cancer.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
